U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07502768) titled 'Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma' on March 20.
Brief Summary: This is a multicenter, open-label, phase Ib/II study evaluating tislelizumab in combination with zeprumetostat (SHR2554) in patients with relapsed or refractory NK/T-cell lymphoma after at least one prior asparaginase-based chemotherapy-containing regimen, with or without radiotherapy. In phase Ib, two fixed dose levels of zeprumetostat in combination with tislelizumab will be evaluated to determine the recommended phase II dose (RP2D). In phase II, patients will be enrolled into 2 predefined cohorts according to prior exposure...